Please assess the completion status of the following clinical trial:

Trial Title: Mupirocin Ointment to Eliminate Nasal Carriage of Staphylococcus Aureus in HIV Infection

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Resident at Project Samaritan Inc. (PSI)~Exclusion Criteria:~* Past hypersensitivity to mupirocin or glycerol~* Pregnancy~* Lactation~* Expected discharge from PSI in the following month~* Treatment with intranasal mupirocin within the preceding two months

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Mupirocin ointment (Type: ACTIVE_COMPARATOR): 0.25g mupirocin calcium ointment, 2% in each nostril twice daily for 5 days (repeated monthly for up to 8 months)
- Placebo ointment (Type: PLACEBO_COMPARATOR): 0.25g in each nostril twice daily for 5 days (repeated monthly for up to 8 months)

Based on this trial design, predict the completion outcome and termination type (if applicable).